EGFR Inhibitor Polymorphs for Selective Mutant Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current EGFR inhibitors face challenges in selectivity, leading to skin and gastrointestinal damage, and resistance in treating EGFR-T790M mutant tumors, while also lacking efficacy for EGFR-activated mutants like EGFR-L858R and delE746_A750.
Innovation Solution
Development of free base or acid salt polymorphs of a specific EGFR inhibitor, such as N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide, which improves physical and chemical properties like crystallinity, solubility, and stability, and includes various salt forms to enhance therapeutic efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If a small molecule EGFR inhibitor with high selectivity for EGFR T790M mutant is developed, then skin and gastrointestinal damage is reduced, but efficacy against EGFR-activated mutants (EGFR-L858R and delE746_A750) is lost
Solution Approach 1:
The patent modifies the chemical structure parameters of the EGFR inhibitor by introducing specific substituent groups (R1-R6 positions) that tune the molecule's binding affinity. By adjusting these structural parameters, the drug achieves broad-spectrum activity against multiple EGFR mutation types while maintaining selective inhibition that reduces off-target effects on wild-type EGFR, thereby resolving the contradiction between reduced side effects and maintained efficacy.
2Quantity of substance
If the compound is developed in amorphous form, then initial solubility is achieved, but physical and chemical stability deteriorates
Solution Approach 1:
The patent employs phase transition technology by converting the amorphous compound into distinct crystalline polymorphs (Polymorph A, B, C, D) with defined X-ray diffraction patterns. This phase transition from amorphous to crystalline state dramatically improves physical and chemical stability while maintaining adequate solubility through controlled crystal lattice structures, directly resolving the stability-solubility contradiction.
3Stability of the object's composition
If polymorphs of the EGFR inhibitor are developed, then physical and chemical stability and solubility are improved, but manufacturing complexity increases
Solution Approach 1:
The patent performs preliminary action by pre-characterizing multiple polymorphic forms and selecting the most manufacturable ones (Polymorphs A-D) with well-defined crystallization behaviors. By establishing standardized preparation methods and characterization protocols for each polymorph beforehand, the patent simplifies subsequent manufacturing processes, quality control, and regulatory approval, thereby reducing the complexity burden despite having multiple polymorphic options.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymorphs of the EGFR inhibitor exhibit improved physical and chemical stability, solubility, and selectivity, reducing side effects and maintaining inhibitory activity against EGFR mutants, making them suitable for clinical use as a first-line therapeutic drug.
Implementation Method 1
the inventors have intensively studied the different aggregation states of the free base or acid salt of the compound of formula I to obtain a number of the free base or acid salt polymorphs of the compound of formula I, which can greatly improve the physical and chemical properties of the amorphous form of the compound of formula I, such as crystallinity, solubility, hygroscopicity and chemical stability
Data Source
AI summary
Disclosed are an EGFR inhibitor free base or acid salt polycrystalline form, a preparation method therefor, and an application thereof. The present invention specifically relates to an N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide free base or acid salt polycrystalline form, a preparation method therefor, and an application of the polycrystalline form in preparing a drug for treating an EGFR mutant activity-mediated disease. The present invention is used for inhibiting the activity of an L858R EGFR mutant, a T790M EGFR mutant and an exon 19 deletion activating mutant etc., may be widely applied in preventing and treating cancer, especially non-small cell lung cancer and other related diseases, and is expected to develop into a new generation of EGFR inhibitors.